Trials of Nasal Spray Version of Sputnik V Vaccine Begin Next Week

It has been stated that clinical trials of the nasal spray version of the Sputnik V coronavirus vaccine developed in Russia will begin next week. Aleksandr Gintsburg, Director of the Gamaleya Institute, the developer of the Sputnik V vaccine, stated that the clinical trials of the Sputnik V vaccine, which they developed as a nasal spray, on volunteers will begin next week. Aleksandr Gintsburg added that the first two phases of the trials will take three months. The director of the Gamaleya Institute stated that if they believe the vaccine is safe and effective in the first and second stages of the trials, they can request an emergency use authorization for the vaccine, so that the vaccine can be made available to the public early. Aleksandr Gintsburg also said that the vaccine in nasal spray form will help prevent the spread of the Covid-19 Omicron variant. The Russian Ministry of Health has approved clinical trials of the nasal spray version of the Sputnik V vaccine to begin in October. The Russian government has allocated 187.8 million rubles ($2.5 million) from the budget for the first and second phase trials of the Sputnik V vaccine. The Sputnik V vaccine was developed in Russia by a method called a viral vector. This method used in the Sputnik V vaccine uses an attenuated virus to transport coronavirus particles to other parts of the body. Thanks to this method, the body is exposed to part of the genetic code of the coronavirus. This makes it possible for the immune system to fight the coronavirus when it actually encounters it. The proven high protection against coronavirus of the Sputnik V vaccine, which has an effectiveness rate of 97.6%, has been documented by many scientific publications, including the British The Lancet.